BioAge, BKV shares end their first trading day flat after earlier gains
Obesity-drug developer BioAge held on to a slim gain after rising more than 20%, while Texas-based Barnett Shale driller BKV ...
FierceBiotech2d
BioAge brings in almost $200M from IPO as obesity biotech joins Nasdaq
BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its ...
Ryan Reynolds's MNTN Explores Going Public as the IPO Market Shows Signs of Thawing
After BioAge Labs raised nearly $200 million in its IPO this week, several companies are beginning to eye the public markets, ...
BioAge valued at $758 mln in debut as investors bet on weight-loss drug frenzy
Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.
BioAge Labs Inc.
BIOAGE discovers and develops drugs to treat aging and associated diseases. The company's primary initiative, azelaprag, is an oral APJ agonist on track for Phase 2 trials in conjunction with ...
BioAge seeks nearly $200 million in initial public offering
BioAge Labs Inc., which has turned its aging diseases focus toward the hot area of obesity drugs, hopes to raise up to close ...